期刊文献+

丙种球蛋白无反应性川崎病相关因素及治疗探讨 被引量:13

Risk factors and retreatment of IVIG nonresponsiveness
暂未订购
导出
摘要 目的:探讨首次静脉丙种球蛋白(IVIG)治疗无反应性川崎病的相关因素及再治疗结果。方法:分析总结2005年3月~2009年2月在本院收治的川崎病患儿的病历资料。IVIG无反应性定义为首次IVIG治疗48小时后体温仍超过38℃。初治有效者为敏感组,无效者为无反应组,对两组患儿临床表现及实验室数据进行统计分析。结果:281例符合川崎病的诊断标准患儿,急性期应用IVIG治疗,其中12例对首次IVIG无反应,发生率4.27%,与敏感组相比,该组全血白细胞计数(WBC)、中性粒细胞百分比(N%)、血沉(ESR)明显升高(P<0.05),冠脉病变(CAL)发生率增高(P<0.01);再治疗选择中,无反应组12例全部接受IVIG2g/(kg.d)1次再次治疗,有效10例,占83.3%,2例对IVIG仍无反应,予糖皮质激素治疗后好转。结论:本组病例中IVIG无反应川崎病发生率约4.27%,其特点为WBC、N%、ESR较高,冠脉病变发生率高。对初次IVIG无效患儿可再次使用静脉丙球治疗,若仍无效可予糖皮质激素治疗。 Objective:To evaluate the risk factors of children with refractory Kawasaki disease(KD)and report the outcome of retreatment.Methods:Clinical data of all children with KD in Nanjing Children’s Hospital were summarized from 2005 through 2009.Refractory KD was defined as those who remained febrile with a temperature beyond 38℃,48 hours after initial intravenous immunoglobulin treatment(IVIG).Results:A totle of 281 patients were included as study subjects.They received initial IVIG therapy in acute phase,and 12 did not respond to the initial IVIG therapy with an incidence of 4.27%(12/281).We found that ESR,WBC,percentage of neutrophil were risk factors for refractory KD(P〈0.05).They had a higher prevalence of CAL at the acute phase(P〈0.01).Children with refractory KD were retreated with a second IVIG of 2 g/kg in 12 patients with 10 responding(83.3%).Steroid was used in 2 children with both responding.Conclusion:The incidence of refractory KD in Nanjing Children’s Hospital is 4.27%.ESR,WBC and percentage of neutrophil are risk factors for refractory KD.Refractory KD has a higher prevalence of CAL at the acute phase.Retreated of children with refractory KD with a 2 g/Kg IVIG is probably more effective.For those who remain febrile after two doses of IVIG can pulse methylprednisolone.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2010年第11期1036-1038,共3页 Chinese Journal of Immunology
关键词 川崎病 静脉丙种球蛋白 无反应性 Kawasaki disease Intravenous immunoglobuhn Nonresponsiveness
  • 相关文献

参考文献11

  • 1王永清,曹晓军.静脉注射丙种球蛋白无反应型川崎病的诊治现状[J].中华儿科杂志,2005,43(3):226-228. 被引量:43
  • 2Hashino K,Ishii M,Iemura M et al.Re-treatment for immune globulin-resistant Kawasaki disease:a comparative study of additional immune globulin and steroid pulse therapy[J].Pediatr Int,2001;43:211-217.
  • 3Newburger J W,Takahashi M,Gerber M A et al.Diagnosis,treatment,and long-term management of Kawasaki disease:a statement for health professionals from committee on rheumatic fever,endocarditis,and Kawasaki disease council on cardiovascular disease in the young American Heart Association[J].Circulation,2004;110:2747-2771.
  • 4Freem an A F,Shulman S T.Refractory Kawasaki disease[J].Pediatr Infect Dis J,2004;23(5):463-464.
  • 5Durongpisit kul K,Soongswang J,Laohaprasitipom D et al.Immunoglobulin failure and retreatment in Kawasaki disease[J].Pediatr Cardiol,2003;24(2):145-148.
  • 6杨军,黄惠君,李成荣.静脉注射免疫球蛋白非敏感型川崎病4例[J].实用儿科临床杂志,2002,17(5):463-464. 被引量:9
  • 7Fukunishi M,Kikkawa M,Hamana K et al.Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset[J].J Prediatr,2000;137:172-176.
  • 8Tohru Kobayashi M D,Yoshinari Inoue M D,Kazuo Takeuchi M D et al.Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease[J].Circulation,2006;112:2606-2612.
  • 9Hung J J,Chiu C H.Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease:case report and review of the literature[J].Ann Trop Paediatr,2004;24:89-93.
  • 10Al-Mayouf S M.The use of corticosteroid therapy in refractory Kawasaki patients[J].Clin Rheumatol,2004;23:11-13.

二级参考文献44

  • 1Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int, 2001,43:211-217.
  • 2Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr,1996,128:146-149.
  • 3Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics, 2000,105:E78.
  • 4Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child, 2002,86:286-290.
  • 5Fukunishi M, Kikkawa M, Hamana K,et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr, 2000,137:172-176.
  • 6Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J, 1998,17:1144-1148.
  • 7Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med, 1991,324:1633-1639.
  • 8Newburger JW, Taubert KA, Shulman ST, et al. Summary and abstracts of the seventh international Kawasaki disease symposium December 4-7, 2001, Hakone, Japan. Pediatr Res, 2003,53:153-157.
  • 9Fong NC, Hui YW, Li CK, et al. Evaluation of the efficacy of treatment of Kawasaki disease before Day 5 of illness. Pediatr Cardiol, 2004,25:31-34.
  • 10Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr, 2002,41:597-601.

共引文献55

同被引文献119

引证文献13

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部